{"title":"高脂血症:第二部分。药物管理","authors":"N. Link, M. Tanner","doi":"10.1136/EWJM.175.6.396","DOIUrl":null,"url":null,"abstract":"Pharmacologic therapy for lipid disorders is now dominated by hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). They have been conclusively proved to prevent coronary events and save lives in a wide variety of situations and are acceptably safe. \n \n \n \nAlternatives to statins include resins (eg, cholestyramine), fibric acid derivatives (eg, gemfibrozil), and nicotinic acid (table 1, see p 400). They all have a place in lipid management but should be considered second-line agents. \n \n \n \nTable 1 \n \nAgents for treating hyperlipidemia","PeriodicalId":22925,"journal":{"name":"The Western journal of medicine","volume":"10 1","pages":"396-401"},"PeriodicalIF":0.0000,"publicationDate":"2001-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hyperlipidemia : Part 2. Pharmacologic management\",\"authors\":\"N. Link, M. Tanner\",\"doi\":\"10.1136/EWJM.175.6.396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pharmacologic therapy for lipid disorders is now dominated by hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). They have been conclusively proved to prevent coronary events and save lives in a wide variety of situations and are acceptably safe. \\n \\n \\n \\nAlternatives to statins include resins (eg, cholestyramine), fibric acid derivatives (eg, gemfibrozil), and nicotinic acid (table 1, see p 400). They all have a place in lipid management but should be considered second-line agents. \\n \\n \\n \\nTable 1 \\n \\nAgents for treating hyperlipidemia\",\"PeriodicalId\":22925,\"journal\":{\"name\":\"The Western journal of medicine\",\"volume\":\"10 1\",\"pages\":\"396-401\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2001-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Western journal of medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/EWJM.175.6.396\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Western journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/EWJM.175.6.396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pharmacologic therapy for lipid disorders is now dominated by hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). They have been conclusively proved to prevent coronary events and save lives in a wide variety of situations and are acceptably safe.
Alternatives to statins include resins (eg, cholestyramine), fibric acid derivatives (eg, gemfibrozil), and nicotinic acid (table 1, see p 400). They all have a place in lipid management but should be considered second-line agents.
Table 1
Agents for treating hyperlipidemia